12:00 AM
 | 
Jun 14, 2010
 |  BC Week In Review  |  Company News  |  Deals

Aoxing, Phoenix PharmaLabs deal

Aoxing received an exclusive license to develop and commercialize undisclosed preclinical compounds from Phoenix PharmaLabs targeting the mu ( OPRM1) (MOR), delta 1 ( OPRD1) (DOR) and kappa...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >